Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus + lactobacillus casei
- Development stage
- Unknown
- Lead developer
- Bio-K+
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus acidophilus + Lactobacillus casei is a probiotic combination product, most notably represented by the Bio-K+ formulation which contains the specific strains CL1285 and LBC80R. This combination is used to maintain and restore the balance of the intestinal microbiota, particularly in the context of antibiotic use. It works through competitive exclusion of pathogens, production of antimicrobial substances like lactic acid, and modulation of the host immune system. Clinical evidence supports its use for the prevention of antibiotic-associated diarrhea (AAD) and Clostridioides difficile infections (CDI), as well as for managing symptoms of irritable bowel syndrome (IBS). The product is available in various oral forms, including capsules and fermented milk liquids.
- Brand names
- Bio-K+
- Other names
- Lactobacillus acidophilus CL1285 + Lactobacillus casei LBC80RBio-K Plus
Beyond the preview
Go deeper on lactobacillus acidophilus + lactobacillus casei.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus + lactobacillus casei.